TScan Therapeutics, Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
TScan announced a strategic reorganization in September 2026 to prioritize in vivo-engineered TCR-T therapy for solid tumors (PRAME and MAGE-A4 targets), advancing both candidates to IND-enabling studies with first patient dosing targeted for Q4 2027. The company paused enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital and is seeking strategic partners for hematologic malignancies and autoimmunity programs. Cash position of $73.0M as of September 30, 2026, is projected to fund operations into Q4 2027; the company missed certain debt milestones by June 30, 2026, triggering amortization of a two-year term loan beginning Q4 2026.
Why this rating
Strategic pivot and Phase 3 pause represent major program deprioritization. $73M cash runway into Q4 2027 provides ~15 months of operations—tight for biotech. Cash burn ~$33M/quarter. Reorganization materially redirects R&D focus; solid tumor failure to launch would be existential at this scale.
Tradability signal
NO TRADE
No trade: price $0.18 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
at our read · unknown $0.19 | +10 min · unknown $0.18 ▼ 2.05% | +30 min · unknown $0.18 ▼ 3.61% | +1 hr · unknown $0.17 ▼ 6.14% | +4 hrs · unknown $0.17 ▼ 7.06% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.